RADX

Radiopharm Theranostics Ltd

• Benzinga·6d ago

  This HC Wainwright & Co. Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

• Benzinga·6d ago

  HC Wainwright & Co. Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $16

• TipRanks·6d ago

  Radiopharm initiated with a Buy at H.C. Wainwright

• PUBT·05/07 01:09

  Radiopharm Theranostics files Form 3 for Chief Medical Officer Dimitris Voliotis

• PUBT·05/06 10:09

  Radiopharm Theranostics director Paul Hopper files initial beneficial ownership statement

• PUBT·05/01 01:52

  Radiopharm Theranostics files Form 3 for CFO Aaron James Laurita

• PUBT·04/23 11:12

  Radiopharm starts first-in-human Phase 1 trial of RAD 402 in advanced prostate cancer

• Benzinga·04/23 11:08

  Radiopharm Theranostics Issues Business Update

• TipRanks·04/20 12:08

  Radiopharm announces new data from Phase 0/1 HEAT trial

• Benzinga·04/20 11:04

  Radiopharm Theranostics Announces That New Data From The Ongoing Phase 0/1 Heat Trial Evaluating 177Lu-RAD202, A First-In-Class HER2-targeted Radiopharmaceutical Therapy, Will Be Presented As A Poster At The American Association For Cancer Research Annual Meeting on April 17–22

• PUBT·04/20 11:01

  Radiopharm Theranostics reports Phase 1 HEAT trial data for 177Lu-RAD202 in HER2+ tumors

• PUBT·04/16 12:03

  Radiopharm completes enrollment in US Phase 2b RAD 101 brain metastases imaging trial

• Benzinga·04/16 11:04

  Radiopharm Announces Dosing Of Final Patient In Phase 2b Imaging Trial Evaluating RAD 101 In Individuals With Confirmed Recurrent Brain Metastases From Solid Tumors Of Different Origins

• TipRanks·04/08 12:36

  Radiopharm Theranostics Moves HER2 Radiotherapy Candidate RAD202 to Higher Dose in Phase 1 Trial

• TipRanks·04/08 11:45

  Radiopharm gets DSMC recommendation to advance 177Lu-RAD202 to next dose